Chair-to-lab workflow for oral brush biopsy · Illustrative demo on sample datahello@brushbiopsy.com
BrushBiopsy
For dental groups, cytology labs and screening programmes

Every brush biopsy, tracked from the chair to the lab and back.

BrushBiopsy is an open, lab-neutral rail for oral brush biopsy: kit orders, chain-of-custody tracking, a prioritised triage queue for qualified readers, structured reports and a recall register that closes the loop on every atypical result.

389,846
lip and oral cavity cancers worldwide, 2022 WHO
D7288
US dental code for transepithelial brush sampling CDT
app.brushbiopsy.com/overviewSample data

Overview

Northgate Dental Group · 8 practices · week 46
New kit order
Samples this week128+17 vs last week
Median chair-to-report31 htarget 72 h
Awaiting reader92 prioritised
Open recalls31 overdue
Samples per week
Wk 35Wk 46
Pipeline
  • Ordered14
  • Collected22
  • In transit31
  • Received18
  • Imaged12
  • In review9
  • Reported22
SamplePracticeSiteStageElapsed
BB-24817Northgate Dental GroupLeft lateral tongueIn review41 h
BB-24822St Anne's DentalFloor of mouthIn review38 h
BB-24830Quayside Dental CareBuccal mucosa (R)In review30 h
BB-24833Elm Row PracticeHard palateImaged26 h
BB-24841Harbour Lane DentalLower lip (vermilion)In review34 h
BB-24846Riverside Smile ClinicGingiva (lower anterior)Received18 h
Clinician and lab overview — volumes, pipeline and turnaround (sample data)
The platform

One rail, six steps, nothing lost in the post.

  1. 01Order

    The practice orders a labelled kit; the sample is routed to the nearest partner lab.

  2. 02Collect

    A painless brush sample from a white or red patch, barcoded at the chair.

  3. 03Track

    Chain of custody from courier scan to lab receipt, with turnaround alerts.

  4. 04Triage

    Slides are imaged and queued for a qualified reader, with suspicious regions ordered first.

  5. 05Report

    A structured, signed report returns to the practice system.

  6. 06Recall

    Atypical results stay open until closed with a referral or histology outcome.

Product

Built for the people who handle the sample.

Recreated screens from the working MVP. All practices, labs and samples are fictional.

app.brushbiopsy.com/triageSample data
Queue · Partner Lab North
BB-24817Left lateral tongue
BB-24822Floor of mouth
BB-24841Lower lip (vermilion)
BB-24830Buccal mucosa (R)
BB-24833Hard palate
BB-24861Lateral tongue (R)

BB-24817

Left lateral tongue · white patch 9 mm · 1,840 cells imaged
Priority review

Tiles are ordered for the reader. The reader reviews the full slide and records the category; nothing is reported without sign-off.

No abnormal cellsAtypicalAbnormal — referInadequate
Reader triage queue — prioritised for a qualified reader, who makes every call (sample data)
app.brushbiopsy.com/reports/BB-24822Sample data
Brush cytology report · SAMPLE

BB-24822

Partner Cytology Lab NorthReported 17 Nov 2026 · 14:20
Requesting practiceSt Anne's Dental, Manchester
SiteFloor of mouth
Clinical descriptionRed-white patch, 6 mm
SpecimenTransepithelial brush, adequate
Reader category
Atypical — further review advised

Fictional example text for layout only. A qualified reader records the category and comment. Atypical and abnormal categories automatically open an entry on the practice recall register.

Signed: Reader 07 (sample)sha256 3f9c…a71eRecall opened · due 01 Dec
Report viewer — structured report returned to the practice (fictional sample)
app.brushbiopsy.com/mapSample data
BristolLeedsEdinburghCardiffManchesterNorwichNewcastleBirminghamLab NorthLab South
PracticePartner labCourier route
In motion · 4
BB-24846Received
Cardiff → London
BB-24850In transit
Birmingham → London
BB-24853Collected
Norwich → London
BB-24858In transit
Leeds → Sheffield
Courier SLA
96%delivered next day · last 30 days
Sample-tracking map — practices, couriers and partner labs (stylised map, sample data)
Chain of custody · BB-24841
  1. 09:12CollectedHarbour Lane Dental · kit 77-0193
  2. 11:40Courier scanBristol hub
  3. 07:55 +1dReceivedPartner Lab South · intact seal
  4. 10:30 +1dImagedSlide BB-24841-1
  5. 15:05 +1dReportedReader 03 sign-off
Turnaround, median hours
Collected → received22 h
Received → imaged3 h
Imaged → reported6 h
Chair-to-report 31 h
Recall register
SampleResultActionState
BB-24611AtypicalSpecialist referralOverdue
BB-24702AbnormalScalpel biopsy bookedBooked
BB-24735AtypicalRepeat brush at 3 wksOpen
BB-24760InadequateRepeat sampleClosed
BB-24788AtypicalHistology receivedClosed
Kit stock by practice
Harbour Lane14/20
Northgate6/30
Elm Row18/20
Quayside3/15
Auto-reorder below 30% of par
Why now

A rising burden, a billing code, and no open infrastructure.

389,846

new lip and oral cavity cancers worldwide in 2022, with 188,438 deaths

WHO oral health fact sheet (GLOBOCAN 2022)
~60,480

US oral cavity and pharynx cancers estimated for 2026, with ~13,150 deaths

American Cancer Society
10,825

UK mouth cancer diagnoses a year, a record, up 133% in 20 years

Oral Health Foundation
613,311

lip and oral cavity cancers projected by 2050 from demographic change alone (+57.3%)

Am J Transl Res, Oct 2026

Market, as published by analysts

Definitions differ between reports, so figures are shown as published and not added together.

FigureSegmentSource
$351M → $527MOral cancer screening devices, 2025 → 2032 (5.96% CAGR)360iResearch via GII
$2.97B → $4.70BOral cancer diagnostics, 2025 → 2035 (4.7% CAGR)Exactitude Consultancy
~$1.5BDigital pathology, 2025, growing 8.6% a year to 2033Grand View Research
57.9%Share of oral screening systems bought by dental clinics in 2025Emergen Research
A billing code already exists

US dentistry bills brush sampling as CDT D7288, “Brush biopsy – transepithelial sample collection”.

cdtcodes.org
AI cytology research is maturing

Deep learning on 2,319 oral brush-cytology whole-slide images matched expert cytopathologists for predicting progression (AUROC 0.730 vs 0.688).

ESMO Real World Data & Digital Oncology, 2026
Regulators have a path for AI cytology

FDA granted Hologic's Genius Cervical AI a De Novo (DEN210035, Class II) in January 2024 — a reader-assist precedent.

FDA De Novo database
Sampling is moving out of the clinic

FDA approved the Teal Wand home cervical self-collection device in May 2025; NHS England began sending HPV self-sampling kits on 25 August 2026.

FDA DEN240045 · NHS Surrey and Sussex Cancer Alliance
Payers want outcome evidence

Anthem's 2026 guideline finds brush-biopsy accuracy variable and not a substitute for scalpel biopsy — the gap a closed-loop register can help fill.

Anthem CG-LAB-12
Who it serves

Three buyers, one shared record.

Dental groups

Order kits, see every sample's status across practices, and never lose an atypical result between appointments.

Cytology laboratories

Offer oral brush cytology without building software: intake, imaging queue, reader sign-off and reporting in one place.

Screening programmes

Run opportunistic or targeted oral screening in high-burden regions with tracked samples and outcome reporting.

Today

A brush sample is posted to one closed laboratory; follow-up lives in the practice's diary.

With BrushBiopsy

Any accredited lab can take the sample, every handover is logged, and the register shows what is still open.

Regulation and safety

Workflow first. AI only through the proper route.

Version 1: not a device

Orders, chain of custody, reporting and recall support qualified professionals and do not analyse images. Readers make every call.

AI module: regulated

Reader-assist cytology AI is a regulated IVD. Planned routes: FDA De Novo or 510(k) (precedent: DEN210035), UKCA via the MHRA, and IVDR Class C with a notified body in the EU.

Data protection

Designed for UK GDPR special-category data, the NHS Data Security and Protection Toolkit and HIPAA. The demo uses no patient data.

Not a diagnostic device

Illustrative product demo only. BrushBiopsy as shown here is not a medical device, is not cleared or approved by any regulator, and does not diagnose, screen for or rule out any disease. All screens use fictional sample data. Clinical decisions must be made by qualified professionals using validated, regulated tests.

Three-year roadmap

An open rail for a test that has a code but no infrastructure.

Year 1

The rail

  • Kit ordering, barcode chain of custody and courier tracking for dental groups
  • Partner-lab triage queue with structured reporting and reader sign-off
  • Recall register for atypical results, with referral and histology closure
Year 2

The reader

  • Whole-slide image viewer with AI-assisted cell prioritisation, validated with partner labs
  • Regulatory submissions planned (US De Novo/510(k), UKCA, IVDR) before any clinical use of the AI module
  • Practice-management and lab-system integrations
Year 3

The network

  • Multi-lab network across the UK, US and one high-burden region
  • Cervical self-sample triage module for HPV-positive follow-up
  • Outcome dataset (brush result versus histology) for payers and guideline bodies
The package

Domain, website, idea, working demo and plan.

  1. Domain brushbiopsy.com, the exact-match name
  2. Website this product site with offer and analytics plumbing
  3. Idea the concept with a three-year roadmap
  4. Working MVP the chair-to-lab demo at /demo
  5. Five-year plan illustrative projections on /acquire
Make your offer✓ 100% equity transfer

Meet the development and tech support team on your introduction call. They stay with the product after the sale, ready to back your five-year roadmap.

Illustrative Year 5, from stated assumptions
Customers210
Revenue$8.1M

Illustrative projections, not a forecast or guarantee. Built only from the assumptions stated here; not actual results. See all five years and assumptions.

FAQ

Straight answers.

Is BrushBiopsy a diagnostic test?

No. The product is workflow, tracking and decision support. Every result is recorded by a qualified reader in an accredited laboratory, and the demo on this site is illustrative only.

Why oral first, rather than cervical?

Cervical cytology is served by large incumbents and is shifting to HPV-primary testing and self-sampling. Oral brush biopsy has a billing code, rising incidence, a single dominant closed lab and little tracking infrastructure. A cervical self-sample triage module is planned for Year 3.

Does BrushBiopsy run a laboratory?

No. Partner laboratories read and bill for the cytology. BrushBiopsy provides the rail between practice and lab and the follow-up register.

What about the AI?

The prioritisation module orders regions for the reader; it does not report. It is planned for validation with partner labs and formal regulatory submissions before any clinical use.